Hope for untreatable cancers.

Cellestia is a privately-owned clinical-stage biopharma led by an experienced
team of scientists, drug developers and business professionals.
Our patented drug, CB-103 along with its companion diagnostic, is a small molecule with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.

WHO WE ARE

We aspire to cure cancer.

WHO WE ARE

We are resolute in our
dedication to patients.

WHO WE ARE

We extend and improve
quality of life.

WHO WE ARE

We are relentless in our
pursuit of pioneering
science.

WHO WE ARE

We do whatever it takes to
adapt to the unknown and
shape the future.

WHO WE ARE

We are all in.

Hope for untreatable cancers.

Cellestia is a privately-owned clinical-stage biopharma led by an experienced
team of scientists, drug developers and business professionals.
Our patented drug, CB-103 along with its companion diagnostic, is a small molecule with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.

WHO WE ARE

We aspire to cure cancer.

WHO WE ARE

We are resolute in our
dedication to patients.

WHO WE ARE

We extend and improve
quality of life.

WHO WE ARE

We are relentless in our
pursuit of pioneering
science.

WHO WE ARE

We do whatever it takes to
adapt to the unknown and
shape the future.

WHO WE ARE

We are all in.